Serplulimab
- Generic Name
- Serplulimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2231029-82-4
- Unique Ingredient Identifier
- S3GQZ2K36V
- Indication
用于经过标准治疗失败的、不可切除或转移性高度微卫星不稳定型（MSI-H）成人晚期实体瘤患者。
- Associated Conditions
- -
- Associated Therapies
- -
Second-line Treatment With Serplulimab, Lenvatinib, and Paclitaxel in Advanced Gastric Cancer After Prior Immunotherapy
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-10-19
- Last Posted Date
- 2023-10-19
- Lead Sponsor
- Qilu Hospital of Shandong University
- Target Recruit Count
- 59
- Registration Number
- NCT05585580
- Locations
- 🇨🇳
The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
🇨🇳Qingdao Municipal Hospital（Group）, Qingdao, Shandong, China
🇨🇳Yantai Yuhuangding Hospital, Yantai, Shandong, China
PD-1 Inhibitor Intraperitoneal Perfusion Combined With PRaG Therapy for Malignant Ascites
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-08-15
- Last Posted Date
- 2022-08-15
- Lead Sponsor
- Second Affiliated Hospital of Soochow University
- Target Recruit Count
- 40
- Registration Number
- NCT05501340
A Phase II Study of Serplulimab Plus Bevacizumab in Combination With Chemotherapy in 1L Treatment of Untreated Recurrent or Metastatic Cervical Cancer
- First Posted Date
- 2022-07-05
- Last Posted Date
- 2022-07-05
- Lead Sponsor
- Sichuan Cancer Hospital and Research Institute
- Target Recruit Count
- 48
- Registration Number
- NCT05444374
- Locations
- 🇨🇳
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath